All In Biotech

Drug Trial Radar · NCT05624229

Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 672 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

672

Planned (sponsor's estimate)

Start

Oct 1, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2028

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute Variceal Bleeding (AVB) in patients with liver cirrhosis is a common clinical critical disease. There is little evidence for the effect of proton pump inhibitor (PPI) use in patients with AVB, and there is no study on the efficacy of PPI combined with standard therapy in patients with AVB.

Conditions

  • Upper Gastrointestinal Hemorrhage

Interventions

  • Proton Pump InhibitorsDrug

    PPI infusion continued to use for 5 days in experimental group

  • No Proton Pump InhibitorsDrug

    PPI infusion stopped in standard group after endoscopy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-day treatment failure rateTime frame: 5 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.